EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety

Nandhini Gangadaran iD, Harshal Mamlekar iD, Souvik Saha iD, Rajesh Kashyap iD, Sanjeev Yadav iD, Khaliqur Rahman iD, Ruchi Gupta iD, Mona Vijayaran iD, Manish Singh iD, Dinesh Chandra iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Nandhini Gangadaran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Dasatinib, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Leukemia, Myeloid, Chronic-Phase. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events. Emerging evidence suggests low‐dose dasatinib (50 mg daily) may maintain efficacy with improved safety, but data in imatinib‐resistant CML‐CP remain limited.

Aims

To evaluate the efficacy and safety of low‐dose dasatinib (50 mg daily) in patients with imatinib‐resistant CML‐CP and to identify predictors of treatment response and disease progression. Methods and Results This retrospective cohort study included 53 adults with imatinib‐resistant CML‐CP treated with low‐dose dasatinib at a tertiary center in Northern India (2002–2025). Early molecular response (EMR), major molecular response (MMR), deep molecular response (DMR), progression‐free survival (PFS), overall survival (OS), and adverse events were assessed. Multivariate Cox regression identified predictors of poor response and disease progression. Among 53 patients (median age 50 years), 41.5% achieved MR4.5, 20.8% MR4.0, and 15.1% MMR without DMR. Prior loss of MMR on imatinib significantly correlated with a superior response to dasatinib ( p = 0.002). TKD mutations were present in 32.1%; the T315I mutation, high ELTS risk, and baseline BCR‐ABL1 ⟩ 100% independently predicted poor response. Clinically significant adverse events occurred in 49.1%, primarily cytopenias and pleural effusion. Among our cohort, 22.6% required a TKI switch due to inadequate response and 7.5% due to intolerance.

Conclusion

Low‐dose dasatinib is effective and tolerable in imatinib‐resistant CML‐CP, with nearly two‐thirds achieving DMRs. Predictive biomarkers (T315I mutation, high ELTS risk, high baseline BCR‐ABL1) can guide dose optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibDrug Resistance, NeoplasmProtein Kinase InhibitorsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansImatinib MesylateRetrospective StudiesMaleMiddle AgedAdultFemaleFusion Proteins, bcr-ablAgedTreatment OutcomeIndiaAntineoplastic Agents

Stichwörter der Autor:innen

BCR‐ABL positive chronic myeloid leukemiadasatinibimatinib mesylatepleural effusiontyrosine kinase inhibitors

Substanzen

DasatinibImatinib MesylateProtein Kinase InhibitorsFusion Proteins, bcr-ablAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.

ORCID-Profile: Nandhini Gangadaran, Harshal Mamlekar, Souvik Saha, Rajesh Kashyap, Sanjeev Yadav, Khaliqur Rahman, Ruchi Gupta, Mona Vijayaran, Manish Singh, Dinesh Chandra

Zitieren

APA

Gangadaran, N., Mamlekar, H., Saha, S., Kashyap, R., Yadav, S., Rahman, K., Gupta, R., Vijayaran, M., Singh, M., & Chandra, D. (2026). Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. Cancer Reports. https://doi.org/10.1002/cnr2.70400

Vancouver

Gangadaran N, Mamlekar H, Saha S, Kashyap R, Yadav S, Rahman K, et al. Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. Cancer Reports. 2026. doi:10.1002/cnr2.70400

BibTeX
@article{Gangadaran2026,
  author = {Gangadaran, Nandhini and Mamlekar, Harshal and Saha, Souvik and Kashyap, Rajesh and Yadav, Sanjeev and Rahman, Khaliqur and Gupta, Ruchi and Vijayaran, Mona and Singh, Manish and Chandra, Dinesh},
  title = {Real‐World Outcomes With Low‐Dose Dasatinib (50 mg) in Imatinib‐Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70400}
}
Kostenlos starten →